CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Price, Quote, News and Overview
NYSEARCA:CANF - American Stock Exchange - US13471N3008 - ADR
CANF Quote and Key Statistics
CAN FITE BIOPHARMA LTD-ADR
NYSEARCA:CANF (1/22/2025, 10:45:05 AM)
1.55
-0.03 (-1.9%)
CANF Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -128.91% | ||
| ROE | -307.95% | ||
| Debt/Equity | 0 |
CANF Performance and Technical Analysis
CANF Ownership and Analysts
CANF Latest News and Analysis
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III advanced liver...
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
RAMAT GAN, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a...
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American:...
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Namodenoson is an oral drug with a proven favorable safety profile RAMAT GAN, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd....
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M Ramat Gan,...
About CANF
Company Profile
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Company Info
CAN FITE BIOPHARMA LTD-ADR
26 Ben Gurion Street
Ramat Gan 4951778 IL
CEO: Pnina Fishman
Employees: 5
Company Website: https://www.canfite.com/
Investor Relations: http://ir.canfite.com/
Phone: 97239241114
CANF Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.77 | 299.57B | ||
| AMGN | AMGEN INC | 14.21 | 146.79B | ||
| GILD | GILEAD SCIENCES INC | 20.73 | 114.47B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839.98 | 110.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.24 | 76.09B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.92B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.29B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.46B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.07B | ||
| NTRA | NATERA INC | N/A | 22.58B | ||
| BIIB | BIOGEN INC | 8.71 | 20.72B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.87B |